Minocycline as heart conditioning agent in experimental type 2 diabetes mellitus - an antibacterial drug in heart protection

Naunyn Schmiedebergs Arch Pharmacol. 2022 Apr;395(4):429-444. doi: 10.1007/s00210-021-02179-y. Epub 2022 Feb 3.

Abstract

Cardiovascular diseases, and among them certainly myocardial infarction, remain leading cause of death worldwide. Diabetes increases risk of occurrence as well as adverse outcome of myocardial infarction. Conditioning maneuvers are the most attractive method for alleviating both the consequences of ischemia and reperfusion. Minocycline is a tetracycline derivative which exerts antioxidant, anti-inflammatory, and anti-apoptotic effects. The aim of this study was to assess the protective ability of preconditioning and postconditioning of isolated hearts from healthy and rats with experimentally induced type 2 diabetes with minocycline on functional recovery and redox status after ischemia and reperfusion. The hearts from healthy and diabetic rats were excised and retrogradely perfused according to the Langendorff technique. Using sensor in the left ventricle, the cardiodynamic parameters were recorded and in the samples of the coronary venous effluent oxidative stress biomarkers were analyzed. Minocycline was injected directly into the coronary vessels, in preconditioning 5 min before global ischemia, and in postconditioning during the first 5 min of reperfusion. Results of this study clearly show beneficial effects of minocycline applied both before ischemia and in the first minutes of reperfusion fashion in both healthy and diabetic rat hearts. The most prominent protective effect regarding oxidative stress is related to the decreased production of superoxide anion radical due postconditioning with minocycline in diabetic hearts. Cardiodynamic parameters were significantly improved in minocycline conditioned groups. Superoxide anion radical stands out as the most susceptible to changes induced by minocycline.

Keywords: Cardiodynamics; Heart conditioning; Minocycline; Oxidative stress; Type 2 diabetes.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Type 2* / drug therapy
  • Heart
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Myocardial Reperfusion Injury* / drug therapy
  • Myocardial Reperfusion Injury* / prevention & control
  • Rats

Substances

  • Anti-Bacterial Agents
  • Minocycline